Navigation Links
Boehringer Ingelheim and Micromet Announce Global Collaboration for Multiple Myeloma BiTE Antibody
Date:5/5/2010

or cells, which explains the activity of BiTE antibodies at very low concentrations. Through the killing process, T cells start to proliferate, which leads to an increased number of T cells at the site of attack.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ingenuity Systems Announces Multi-Year Agreement With Boehringer Ingelheim
2. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
3. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
4. More Than Half of Patients Treated for Benign Prostatic Hyperplasia Receive Boehringer Ingelheims Flomax as First-Line Therapy
5. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
6. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
8. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
9. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
10. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
11. Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
(Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
(Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
(Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
... , CORALVILLE, Iowa, Nov. 17 Vivakor, Inc. (OTC ... approved a dividend of shares of common stock of HealthAmerica, ... of the outstanding common stock. Each Vivakor shareholder will ... for each share of Vivakor common stock beneficially owned on ...
... Neuralstem, Inc. (NYSE Amex: CUR ) today provided a financial ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) , ... loss of $5,096,983, or $0.15 per share, compared with a net ... period. The increase was due to a non-cash charge related to ...
... LEIDEN, The Netherlands, November 17 ... with Actelion Pharmaceuticals Ltd,Erasmus Medical Centre and Maastricht ... hypertension (high blood pressure) and associated vascular,complications such as ... novel action mechanisms, new drugs may be discovered with,the ...
Cached Biology Technology:Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications 2
(Date:7/23/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
(Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
(Date:7/23/2014)... Scientists with the NH Agricultural Experiment Station are working ... after new research based on genetic monitoring has found ... New England have become more isolated and seen a ... endangered New England cottontail is now is at risk ... Agricultural Experiment Station researchers at the University of New ...
Breaking Biology News(10 mins):Nano-sized chip "sniffs out" explosives far better than trained dogs 2UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
... The ubiquitous and usually harmless E. coli bacterium, which ... has more than 1,000 of them involved in metabolism ... genes would theoretically be capable of generating a huge ... report in the Dec. 27 issue of Proceedings of ...
... medical doctor. Yet he is seen as a hero by ... was diagnosed with terminal lung cancer. , "In 2000 he ... months to live," said Pardini, a professor of biochemistry and ... University of Nevada, Reno. "But five years later, he ...
... great challenges for treating Parkinson's diseases and other neurodegenerative disorders ... , The brain is a complex organ with many different ... a protective barrier erected by blood vessels and glial cells ... the delivery of most drugs from the bloodstream. , But ...
Cached Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3
ANTI STENOTROPHOMONAS MALTOPHILIA...
... an essential component of the COP9 signalosome ... cellular and developmental processes. The CSN complex ... (Ubl) conjugation pathway by mediating the deneddylation ... ligase complexes. The complex is also involved ...
6B9...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: